Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.

Li, Meng; Liao, Kaiping; Nowakowska, Malgorzata; Wehner, Mackenzie; Shih, Ya-Chen Tina

Li, Meng; Liao, Kaiping; Nowakowska, Malgorzata; Wehner, Mackenzie; Shih, Ya-Chen Tina.

Afiliação

Li M; University of Texas MD Anderson Cancer Center, Department of Health Services Research, Houston.
Liao K; University of Texas MD Anderson Cancer Center, Department of Health Services Research, Houston.
Nowakowska M; University of Texas Southwestern Medical Center, Department of Dermatology, Dallas.
Wehner M; University of Texas MD Anderson Cancer Center, Department of Health Services Research, Houston.
Shih YT; University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston.

J Manag Care Spec Pharm ; 29(11): 1232-1241, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37889870

Assuntos

Medicare Part C; Melanoma; Adulto; Humanos; Idoso; Estados Unidos/epidemiologia; Etnicidade; Estudos Retrospectivos; Grupos Minoritários; Melanoma/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicare Part C / Melanoma Limite: Adult / Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: J Manag Care Spec Pharm Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google